<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000498.pub2" GROUP_ID="NEONATAL" ID="354099090914572109" MERGED_FROM="" MODIFIED="2008-06-10 21:22:51 +0200" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;/p&gt;&lt;p&gt;Short title (no longer in use): Intraventricular streptokinase after IVH&lt;/p&gt;&lt;p&gt;Sent to Loni Apr 2-07&lt;/p&gt;&lt;p&gt;CL 4/07 (substantive update)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-06-10 15:21:24 -0400" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="3" REVMAN_SUB_VERSION="5.0.12" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.2">
<COVER_SHEET MODIFIED="2008-06-10 21:22:51 +0200" MODIFIED_BY="Diane Haughton">
<TITLE>Intraventricular streptokinase after intraventricular hemorrhage in newborn infants</TITLE>
<CONTACT MODIFIED="2008-06-10 21:22:51 +0200" MODIFIED_BY="Diane Haughton"><PERSON ID="8296" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Andrew</FIRST_NAME><LAST_NAME>Whitelaw</LAST_NAME><POSITION>Professor of Pediatrics</POSITION><EMAIL_1>andrew.whitelaw@bristol.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Neonatal Intensive Care Unit</DEPARTMENT><ORGANISATION>University of Bristol</ORGANISATION><ADDRESS_1>Southmead Hospital</ADDRESS_1><CITY>Bristol</CITY><ZIP>BS10 5NB</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+441 117 959 5325</PHONE_1><FAX_1>+441 117 959 5324</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-06-10 21:22:51 +0200" MODIFIED_BY="Diane Haughton"><PERSON ID="8296" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Andrew</FIRST_NAME><LAST_NAME>Whitelaw</LAST_NAME><POSITION>Professor of Pediatrics</POSITION><EMAIL_1>andrew.whitelaw@bristol.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Neonatal Intensive Care Unit</DEPARTMENT><ORGANISATION>University of Bristol</ORGANISATION><ADDRESS_1>Southmead Hospital</ADDRESS_1><CITY>Bristol</CITY><ZIP>BS10 5NB</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+441 117 959 5325</PHONE_1><FAX_1>+441 117 959 5324</FAX_1></ADDRESS></PERSON><PERSON ID="293B3A6082E26AA200CD32E5B89B1DAB" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>David</FIRST_NAME><LAST_NAME>Odd</LAST_NAME><EMAIL_1>davidodd@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>Neonatal Medicine</DEPARTMENT><ORGANISATION>University of Bristol Medical School</ORGANISATION><ADDRESS_1>Southmead Hospital</ADDRESS_1><CITY>Bristol</CITY><ZIP>BS10 5NB</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>44 117 959 5699</PHONE_1></ADDRESS></PERSON><PERSON ID="6592" ROLE="AUTHOR"><FIRST_NAME>Luc</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Brion</LAST_NAME><SUFFIX>M.D.</SUFFIX><POSITION>Professor of Pediatrics</POSITION><EMAIL_1>Luc.Brion@UTSouthwestern.edu</EMAIL_1><ADDRESS><DEPARTMENT>Division of Neonatal-Perinatal Medicine</DEPARTMENT><ORGANISATION>University of Texas Southwestern at Dallas</ORGANISATION><ADDRESS_1>5323 Harry Hines Boulevard</ADDRESS_1><CITY>Dallas</CITY><ZIP>75390-9063</ZIP><REGION>Texas</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>1 214 648 2060</PHONE_1><FAX_1>1 214 648 2481</FAX_1></ADDRESS></PERSON><PERSON ID="15252" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>C</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Kennedy</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Consultant Pediatric Neurologist</POSITION><EMAIL_1>crk1@soton.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Child Health</DEPARTMENT><ORGANISATION>Southampton General Hospital</ORGANISATION><ADDRESS_1>Mailpoint 21, Department of Child Health</ADDRESS_1><ADDRESS_2>Southampton General Hospital, Tremona Road</ADDRESS_2><CITY>Southampton</CITY><ZIP>SO16 6YD</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1703 796 171</PHONE_1><FAX_1>+44 1703 794 962</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-06-10 10:47:53 -0400" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;New studies found and included or excluded: 13/04/07&lt;/p&gt;&lt;p&gt;Conclusions changed: 10/09/99&lt;/p&gt;&lt;p&gt;Reformatted: 09/09/99&lt;/p&gt;" NOTES_MODIFIED="2008-06-10 10:47:53 -0400" NOTES_MODIFIED_BY="Diane Haughton">
<UP_TO_DATE>
<DATE DAY="31" MONTH="5" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="4" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="5" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1997"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2008-06-10 10:35:36 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="10" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-06-10 15:21:24 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-06-10 15:21:24 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="5" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-10 10:44:25 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="5" YEAR="2007"/>
<DESCRIPTION>
<P>This review updates the existing review "Intraventricular streptokinase after intraventricular hemorrhage in newborn infants" published in The Cochrane Library, Issue 1, 2001 (<LINK REF="REF-Whitelaw-2001" TYPE="REFERENCE">Whitelaw 2001</LINK>).<BR/>
<BR/>That review concluded that treatment with intraventricular streptokinase cannot be recommended for established post-hemorrhagic ventricular dilatation.<BR/>
<BR/>Our updated search identified one new randomized trial for inclusion in the review. The updated results and consequently the conclusions remain similar.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Bristol</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Wellcome Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-06-10 10:43:01 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-06-10 10:34:00 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-06-10 10:34:00 -0400" MODIFIED_BY="[Empty name]">Intraventricular streptokinase after intraventricular hemorrhage in newborn infants</TITLE>
<SUMMARY_BODY MODIFIED="2008-06-10 10:33:50 -0400" MODIFIED_BY="[Empty name]">
<P>There is no evidence of benefit from giving streptokinase to newborn babies after brain haemorrhage.Bleeding (hemorrhage) into the ventricles of the brain is a serious complication of premature birth and large hemorrhages often lead to hydrocephalus, the process by which fluid accumulates under pressure inside the brain, expanding the head excessively and damaging the brain tissue. The insertion of a valve and drainage system (ventriculoperitoneal shunt) is fraught with problems in this patient group and alternatives to this therapy are needed. A possible approach is to try to dissolve the blood clots initially blocking the reabsorption of fluid in the brain. Streptokinase is a "clot-busting" agent that has been successfully used to unblock coronary arteries. The review found no good evidence that intraventricular injection of streptokinase to infants with large intraventricular hemorrhage or post-hemorrhagic ventricular enlargement reduces the need for ventriculoperitoneal shunt or improves outcome.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Hydrocephalus following intraventricular hemorrhage (IVH) is still one of the most serious complications of premature birth. Ventriculoperitoneal shunt surgery cannot be carried out early and permanent dependence on a shunt is associated with several serious complications. Streptokinase could be useful in the treatment of post-hemorrhagic hydrocephalus. This form of therapy is based on the hypothesis that multiple blood clots in the cerebrospinal fluid (CSF) are the initial cause of post-hemorrhagic ventricular dilatation and lysis of clots could reopen the pathways of circulation and re-absorption of CSF.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effect of intraventricular streptokinase after intraventricular hemorrhage on the risk of permanent shunt dependence, neurodevelopmental disability or death in neonates at risk for, or actually developing post-hemorrhagic hydrocephalus (PHH). </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Pediatric, Neurosurgical and General Medical Journals were handsearched from 1976 until October 2000, as well as the MEDLINE database (via PubMed) and the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library) up to April 2007. Personal contacts were used.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized controlled trials and quasi-randomized controlled trials evaluating the use of injection of streptokinase into the CSF in infants having or at risk for post-hemorrhagic hydrocephalus.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Details of patient selection, patient allocation and the interventions were extracted. The end-points examined were: ventriculoperitoneal shunt, death, meningitis, and secondary hemorrhage.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Two randomized trials evaluated intraventricular streptokinase in infants developing post-hemorrhagic ventricular dilatation were identified When intraventricular streptokinase was compared with conservative management of post-hemorrhagic ventricular dilatation, the numbers of deaths and babies with shunt dependence were similar in both groups.</P>
<P>No information on the effect of intraventricular streptokinase on disability is available. There is cause for concern about meningitis and secondary intraventricular hemorrhage, but numbers are insufficient to quantify the risks.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Intraventricular fibrinolytic therapy with streptokinase, given when post-hemorrhagic ventricular dilatation is established, cannot be recommended for neonates following IVH. A conservative approach with CSF drainage applied only to symptomatic raised intracranial pressure seems appropriate.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-06-10 10:43:01 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-06-10 10:43:01 -0400" MODIFIED_BY="[Empty name]">
<P>Although many interventions have been shown to reduce the risk of intraventricular hemorrhage (IVH), it is still a common consequence of premature birth. post-hemorrhagic hydrocephalus (PHH) is the most serious complication of IVH. The risk of PHH is related to the size of the original hemorrhage and the initial mechanism is thought to be blockage of the channels of CSF reabsorption by multiple small blood clots (<LINK REF="REF-Hill-1984" TYPE="REFERENCE">Hill 1984</LINK>). Permanent hydrocephalus is thought to result from inward migration of fibroblasts and collagen deposition in the CSF pathways. Early insertion of a ventriculoperitoneal shunt is fraught with complications and delayed shunt operations in small prematures have a high rate of blockage and infection (<LINK REF="REF-Punt-1995" TYPE="REFERENCE">Punt 1995</LINK>). Furthermore, these infants are nearly always shunt-dependent for the rest of their lives and require several later operations even if no other problems occur. Therefore, it would be a great advantage if treatment could reduce the risk of permanent hydrocephalus after established IVH.</P>
<P>Neurodevelopmental outcome is poor in infants with PHH. Although part of this is because of parenchymal brain lesions present before PHH developed, it is likely that some of the dysfunction is the result of prolonged periods with raised intracranial pressure with periventricular edema and distortion of the developing axonal pathways and their myelination.<BR/>
<BR/>It has been postulated that early removal of bloody CSF by lumbar or ventricular tap might improve the prognosis of infants at risk of, or actually developing, PHH and this is the subject of another Cochrane review which concluded that early tapping after IVH could not be recommended.</P>
<P>It has been suggested that increasing the lysis of blood clots in the CSF by intraventricular injection of plasminogen activator might restore the circulation of CSF and prevent permanent hydrocephalus. Five small open non-randomized (phase 1) studies with streptokinase, urokinase or tissue plasminogen activator have been carried out, looking at measurable acute changes, drug delivery methods, pharmacokinetics and short term outcome (<LINK REF="REF-Whitelaw--1992" TYPE="REFERENCE">Whitelaw 1992</LINK>; <LINK REF="REF-Hudgins-1994" TYPE="REFERENCE">Hudgins 1994</LINK>; <LINK REF="REF-Whitelaw-1996" TYPE="REFERENCE">Whitelaw 1996</LINK>; <LINK REF="REF-Hansen-b-1997" TYPE="REFERENCE">Hansen b 1997</LINK>; <LINK REF="REF-Hudgins-1997" TYPE="REFERENCE">Hudgins 1997</LINK>; <LINK REF="REF-Nowak-1999" TYPE="REFERENCE">Nowak 1999</LINK>). The number of infants included is small and the results vary from 100% success (<LINK REF="REF-Hudgins-1994" TYPE="REFERENCE">Hudgins 1994</LINK>) to 100% failure (<LINK REF="REF-Hansen-b-1997" TYPE="REFERENCE">Hansen b 1997</LINK>) in terms of avoiding shunt surgery.</P>
<P>Another therapeutic approach is to use drugs which reduce the production of CSF. Both acetazolamide and furosemide produce substantial reductions in CSF production and these two drugs in combination have been used in an uncontrolled open trial of infants developing post-hemorrhagic hydrocephalus (<LINK REF="REF-Shinnar-1985" TYPE="REFERENCE">Shinnar 1985</LINK>). This treatment strategy has now been tested in a large multicentre randomized trial, the <LINK REF="REF-PHVD-Trial-1998" TYPE="REFERENCE">PHVD Trial 1998</LINK>, which found that the risk of death or shunt surgery was increased in the infants treated with acetazolamide and furosemide.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The objectives of this review are to examine the effect of intraventricular treatment with streptokinase after IVH or early PHH on:<BR/>a) the need for a permanent shunt <BR/>b) neurodevelopmental outcome or survival<BR/>c) adverse effects such as meningitis or secondary bleeding</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All controlled trials whether truly randomized or quasi-randomized in which intraventricular fibrinolytic therapy was compared to standard (control) treatment in newborn infants with IVH or early PHH were to be identified. Treatment by injection of plasminogen activator cannot be done 'blind' by the neonatologist but the assessment of outcome could be carried out by individuals blind to early treatment allocation.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Infants of less than three months of age with a) IVH demonstrated by ultrasound or CT scan ( at risk of PHH) or b) infants with IVH followed by progressive ventricular dilatation were included. Infants with other causes of hydrocephalus (e.g. infection, congenital aqueduct stenosis, tumour) were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Injection of streptokinase into the CSF</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The main outcomes of interest are the number of children <BR/>a) acquiring permanent shunts <BR/>b) dying during follow-up <BR/>c) meningitis during treatment <BR/>d) secondary intraventricular hemorrhage during treatment</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>The reviewer has been an active trialist in this area and has personal contact with many groups in this field. Journals handsearched from January 1976 (when CT scanning of neonates started) to October 2000 include: Pediatrics, J Pediatrics, Archives of Disease in Childhood, Pediatric Research, Developmental Medicine and Child Neurology, Acta Paediatrica Scandinavica, Child's Nervous System, European J of Pediatrics, Neuropediatrics, Neurosurgery, J Neurosurgery, Pediatric Neurosurgery, Biology of the Neonate, New England J Medicine, Lancet, British Medical Journal. The MEDLINE database (via PubMed) and the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library) were searched from January 1976 to April 2007 using the MeSH terms streptokinase, intraventricular hemorrhage, hydrocephalus, newborn infant. Proceedings of the Society for Pediatric Research, European Society for Pediatric Research, Neonatal Society and Royal College of Paediatrics and Child Health were searched by hand from 1988 to 2006.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Each identified trial was assessed for methodological quality with respect to <BR/>a) adequate allocation concealment <BR/>b) method of allocation <BR/>c) performance bias <BR/>d) exclusion bias <BR/>e) bias in outcome assessment.<BR/>Trials without a simultaneous control group ( e.g. those with historical controls) were rejected. <BR/>Inclusion criteria and therapeutic interventions for each trial were reviewed to see how they differed between trials. The outcomes in each trial were examined to see how comparable they were between studies. <BR/>Statistics: 2 X 2 tables were made from each trial for each important outcome and odds ratio, relative risk and risk difference with 95% confidence intervals were used in the meta-analysis.<BR/>Heterogeneity wax examined using the I<SUP>2</SUP> statistic.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-06-10 10:43:01 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION>
<P>See Table, Characteristics of Included Studies.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-06-10 10:43:01 -0400" MODIFIED_BY="[Empty name]">
<P>Searching yielded only two trials that qualified for inclusion.</P>
<P>
<B>Assessment of validity:<BR/>
</B>
<BR/>
<LINK REF="STD-Luciano-1997" TYPE="STUDY">Luciano 1997</LINK>
<BR/>Method of randomization - unclear<BR/>Blinding of caretakers - no<BR/>Almost all subjects analyses - yes<BR/>Blinding of observers - no</P>
<P>
<BR/>
<LINK REF="STD-Yapicioglu-2003" TYPE="STUDY">Yapicioglu 2003</LINK>
<BR/>Method of randomization - unclear<BR/>Blinding of caretakers - no<BR/>Almost all subjects analyses - yes<BR/>Blinding of observers - no<BR/>
</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>
<B>
<BR/>
</B>
<B>INTRAVENTRICULAR STREPTOKINASE AFTER INTRAVENTRICULAR HEMORRHAGE IN NEWBORN INFANTS (COMPARISON 01):</B>
<B>
<BR/>Hydrocephalus shunt (Outcome 01.01):</B>
<BR/>Only two small randomized trials of intraventricular fibrinolytic therapy (streptokinase) were found. The numbers of infants dying or requiring a peritoneal shunt for hydrocephalus were similar in the two groups. Both studies reported on the need for a shunt for hydrocephalus. No difference was noted in the meta-analysis (typical RR 1.33, 95% CI 0.67, 2.67; typical RD 0.17 95% CI -0.21, 0.59). </P>
<P>Side effects of interventions:<BR/>The group of infants who received intraventricular streptokinase had one case of meningitis and one case of secondary intraventricular bleeding, both being likely side-effects of the intervention. However, these differences were not statistically significant.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>The major outcomes (death or shunt) were similar when the two groups were compared, although there is a suggestion that infants receiving streptokinase may have a higher risk for shunt insertion. However the trials of streptokinase were so small that their power to detect a therapeutic effect was limited.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-06-10 10:43:01 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE>
<P>Intraventricular fibrinolytic therapy with streptokinase starting before one month of age in infants developing post-hemorrhagic ventricular dilatation cannot be recommended.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-06-10 10:43:01 -0400" MODIFIED_BY="[Empty name]">
<P>As ventriculoperitoneal shunting is still a treatment with many problems in preterm infants with PHH, alternative therapies are very much needed. Neither early tapping of CSF nor acetazolamide and furosemide are effective in reducing the need for shunting and both forms of therapy have adverse effects.</P>
<P>It may be that the results to date of intraventricular fibrinolytic therapy are negative because the treatment (starting nearly two weeks after birth) has been given too late. Fibrosis, desposition of extracellular matrix proteins and chronic inflammatory changes may already have become irreversible. Furthermore, very low levels of plasminogen (<LINK REF="REF-Whitelaw-1995" TYPE="REFERENCE">Whitelaw 1995</LINK>) and the presence of Plasminogen Activator Inhibitor-1 (PAI-1) ( <LINK REF="REF-Hansen-a-1997" TYPE="REFERENCE">Hansen a 1997</LINK>) would be expected to limit the fibrinolytic effect of intraventricular streptokinase. There is now considerable evidence that the cytokine, Transforming Growth Factor Beta-1 (TGF beta-1), plays a major role in the development of hydrocephalus after intraventricular haemorrhage and that intraventricular injection of tissue plasminogen activator, on its own, increases the concentration of TGF beta-1 in ventricular CSF (<LINK REF="REF-Whitelaw-1999" TYPE="REFERENCE">Whitelaw 1999</LINK>). This could help to explain the failure of intraventricular injection of fibrinolytic agents to prevent hydrocephalus. Therapeutic strategies need to consider ways of removing, blocking or preventing release of this, and perhaps other, cytokines.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS/>
<CONFLICT_OF_INTEREST>
<P>None<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>DO carried out the updated literature search and wrote the first drafts of the updated review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-06-10 10:28:25 -0400" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Luciano-1997" NAME="Luciano 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Luciano R, Velardi F, Romagnoli C, Papacci P, De Stefano V, Tortorolo G. Failure of fibrinolytic endoventricular treatment to prevent neonatal post-haemorrhagic hydrocephalus. Child's Nervous System 1997;13:73-6&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luciano R, Velardi F, Romagnoli C, Papacci P, De Stefano V, Tortorolo G</AU>
<TI>Failure of fibrinolytic endoventricular treatment to prevent neonatal post-haemorrhagic hydrocephalus</TI>
<SO>Child's Nervous System</SO>
<YR>1997</YR>
<VL>13</VL>
<PG>73-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yapicioglu-2003" NAME="Yapicioglu 2003" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yapicioglu H, Narli N, Satar M, Soyupak S, Altunbasak S</AU>
<TI>Intraventricular streptokinase for the treatment of posthaemorrhagic hydrocephalus of preterm</TI>
<SO>Journal of Clinical Neuroscience</SO>
<YR>2003</YR>
<VL>10</VL>
<PG>297-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12763331"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-06-10 10:28:25 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Hansen-a-1997" NAME="Hansen a 1997" NOTES="&lt;p&gt;Hansen A, Whitelaw A, Lapp C, Brugnara C. Cerebrospinal fluid plasminogen activator inhibitor-1: a prognostic factor in posthaemorrhagic hydrocephalus. Acta Paediatrica 1997 in press.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hansen A, Whitelaw A, Lapp C, Brugnara C</AU>
<TI>Cerebrospinal fluid plasminogen activator inhibitor-1: a prognostic factor in posthaemorrhagic hydrocephalus</TI>
<SO>Acta Paediatrica</SO>
<YR>1997</YR>
<VL>86</VL>
<PG>995-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hansen-b-1997" NAME="Hansen b 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hansen AR, Volpe JJ, Goumnerova LC, Madsen JR</AU>
<TI>Intraventricular urokinase for the treatment of posthemorrhagic hydrocephalus</TI>
<SO>Pediatric Neurology</SO>
<YR>1997</YR>
<VL>17</VL>
<PG>213-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hill-1984" NAME="Hill 1984" TYPE="JOURNAL_ARTICLE">
<AU>Hill A, Shackleford GD, Volpe JJ</AU>
<TI>A potential mechanism of pathogenesis for early posthemorrhagic hydrocephalus in the premature newborn</TI>
<SO>Pediatrics</SO>
<YR>1984</YR>
<VL>73</VL>
<PG>19-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hudgins-1994" NAME="Hudgins 1994" NOTES="&lt;p&gt;Hudgins RJ, Boydston WR, Hudgins PA, Adler SR. Treatment of intraventricular hemorrhage in the premature infant with urokinase. A preliminary study. Pediatr Neurosurg 1994;20:190-7.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hudgins RJ, Boydston WR, Hudgins PA, Adler SR</AU>
<TI>Treatment of intraventricular hemorrhage in the premature infant with urokinase. A preliminary study</TI>
<SO>Pediatric Neurosurgery</SO>
<YR>1994</YR>
<VL>20</VL>
<PG>190-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hudgins-1997" NAME="Hudgins 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hudgins RJ, Boydston WR, Hudgins PA, Morris R, Adler SM, Gilreath CL</AU>
<TI>Intrathecal urokinase as a treatment for intraventricular hemorrhage in the preterm infant</TI>
<SO>Pediatric Neurosurgery</SO>
<YR>1997</YR>
<VL>26</VL>
<PG>281-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9485155"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Levene-1981" NAME="Levene 1981" NOTES="&lt;p&gt;Levene MI. Measurement of the growth of the lateral ventricle in preterm infants with real time ultrasound. Arch Dis Child. 1981;56:900-4.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Levene MI</AU>
<TI>Measurement of the growth of the lateral ventricle in preterm infants with real time ultrasound</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1981</YR>
<VL>56</VL>
<PG>900-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nowak-1999" NAME="Nowak 1999" TYPE="JOURNAL_ARTICLE">
<AU>Nowak S, Rudeck M, Polis L</AU>
<TI>Intraventricular administration of human recombinant plasminogen activator for posthemorrhagic hydrocephalus of the newborn</TI>
<SO>Acta Paediatrica</SO>
<YR>1999</YR>
<VL>88</VL>
<PG>995-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PHVD-Trial-1998" NAME="PHVD Trial 1998" TYPE="JOURNAL_ARTICLE">
<AU>International PHVD Drug Trial Group</AU>
<TI>International randomised controlled trial of acetazolamide and furosemide in posthaemorrhagic ventricular dilatation in infancy</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>433-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Punt-1995" NAME="Punt 1995" NOTES="&lt;p&gt;Punt J. Neurosurgical management of hydrocephalus. In: Levene MI, Lilford RJ, eds. Fetal and neonatal neurology and neurosurgery. Edinburgh: Churchill Livingstone. 1995:661-6.&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Punt J</AU>
<TI>Neurosurgical management of hydrocephalus</TI>
<SO>Fetal and Neonatal Neurology and Neurosurgery</SO>
<YR>1995</YR>
<PG>661-6</PG>
<ED>Levene MI, Lilford RJ</ED>
<PB>Churchill Livingstone</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shinnar-1985" NAME="Shinnar 1985" NOTES="&lt;p&gt;Shinnar S, Gammon K, Bergman EW, Epstein M, Freedom JM. Management of hydrocephalus in infancy: use of acetazolamide and furosemide to avoid cerebrospinal fluid shunts. J Pediatrics 1985;107:31-6.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Shinnar S, Gammon K, Bergman EW, Epstein M, Freedom JM</AU>
<TI>Management of hydrocephalus in infancy: use of acetazolamide and furosemide to avoid cerebrospinal fluid shunts</TI>
<SO>Journal of Pediatrics</SO>
<YR>1985</YR>
<VL>107</VL>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitelaw--1992" NAME="Whitelaw  1992" NOTES="&lt;p&gt;Whitelaw A, Rivers R, Creighton L, Gaffney P. Low dose intraventricular fibrinolytic therapy to prevent posthaemorrhagic hydrocephalus. Arch Dis Child 1992;67:F12-4.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Whitelaw A, Rivers R, Creighton L, Gaffney P</AU>
<TI>Low dose intraventricular fibrinolytic therapy to prevent posthaemorrhagic hydrocephalus</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1992</YR>
<VL>67</VL>
<PG>F12-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitelaw-1995" NAME="Whitelaw 1995" NOTES="&lt;p&gt;Whitelaw A, Mowinckel M-C, Abildgaard U. Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis? Acta Paediatrica 1995;84:933-6&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Whitelaw A, Mowinckel M-C, Abildgaard U</AU>
<TI>Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis?</TI>
<SO>Acta Paediatrica</SO>
<YR>1995</YR>
<VL>84</VL>
<PG>933-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitelaw-1996" NAME="Whitelaw 1996" NOTES="&lt;p&gt;Whitelaw A, Saliba E, Fellman V, Mowinckel M-C, Acolet D, Marlow N. Phase 1 study of intraventricular recombinant tissue plasminogen activator for treatment of posthaemorrhagic hydrocephalus. Arch Dis Child 1996;74:F20-6.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Whitelaw A, Saliba E, Fellman V, Mowinckel M-C, Acolet D, Marlow N</AU>
<TI>Phase 1 study of intraventricular recombinant tissue plasminogen activator for treatment of posthaemorrhagic hydrocephalus</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1996</YR>
<VL>74</VL>
<PG>F20-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitelaw-1999" NAME="Whitelaw 1999" TYPE="JOURNAL_ARTICLE">
<AU>Whitelaw A, Christie S, Pople I</AU>
<TI>Transforming Growth Factor Beta-1: A possible signal molecule for posthemorrhagic hydrocephalus</TI>
<SO>Pediatric Research</SO>
<YR>1999</YR>
<VL>46</VL>
<PG>576-80</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-06-10 10:28:25 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Whitelaw-2000" MODIFIED="2008-06-10 10:26:34 -0400" MODIFIED_BY="[Empty name]" NAME="Whitelaw 2000" TYPE="COCHRANE_REVIEW">
<AU>A Whitelaw</AU>
<TI>Intraventricular streptokinase after intraventricular hemorrhage in newborn infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-06-10 10:26:34 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-06-10 10:26:34 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000498"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Whitelaw-2001" MODIFIED="2008-06-10 10:28:25 -0400" MODIFIED_BY="[Empty name]" NAME="Whitelaw 2001" TYPE="COCHRANE_REVIEW">
<AU>A Whitelaw</AU>
<TI>Intraventricular streptokinase after intraventricular hemorrhage in newborn infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-06-10 10:28:25 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-06-10 10:28:24 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000498"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Luciano-1997">
<CHAR_METHODS>
<P>Open randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>12 newborn infants who were shown by ultrasound to have intraventricular hemorrhage followed by progressive enlargement to 4 mm over the 97th centile for ventricular width</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Insertion of a percutaneous ventricular catheter via the anterior fontanelle. Streptokinase 20,000 units/day was given intraventricularly for 96 hours. CSF drainage was performed several times a day to prevent raised intracranial pressure.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death, insertion of a ventriculoperitoneal shunt, meningitis and secondary intraventricular bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yapicioglu-2003">
<CHAR_METHODS>
<P>Open randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>12 newborn infants who developed posthaemorrhagic hydrocephalus.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Lumber puncture to remove 5-10ml of CSF, followed by insertion of a percutaneous ventricular catheter via the anterior fontanelle, and removal of a further 5ml of CSF. Streptokinase 25,000 units over 3 days at 0.5ml/h was given intraventricularly. CSF drainage of 5-10ml of CSF was performed once a day. Intraventicular vancomycin (1mg/day) for infection prophylaxis.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Third ventricular size, death, insertion of a ventriculoperitoneal shunt, meningitis and secondary intraventricular bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Luciano-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yapicioglu-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-06-10 10:42:09 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-06-10 10:42:09 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Intraventricular streptokinase vs control</NAME>
<DICH_OUTCOME CHI2="0.497248146896042" CI_END="2.666146001809397" CI_START="0.6667968583008123" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.42588392829013927" LOG_CI_START="-0.1760064550735394" LOG_EFFECT_SIZE="0.12493873660829992" METHOD="MH" MODIFIED="2008-06-10 10:41:40 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4807118152682258" P_Q="0.0" P_Z="0.4158238457081066" Q="0.0" RANDOM="NO" SCALE="4.015806686017903" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.8136877770258156">
<NAME>Hydrocephalus shunt</NAME>
<GROUP_LABEL_1>Fibrinolytic therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Fibrinolytic therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1005692822786637" CI_START="0.3225214175072657" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.491441440109722" LOG_CI_START="-0.491441440109722" LOG_EFFECT_SIZE="0.0" ORDER="5" O_E="0.0" SE="0.5773502691896258" STUDY_ID="STD-Luciano-1997" TOTAL_1="6" TOTAL_2="6" VAR="0.33333333333333337" WEIGHT="50.0"/>
<DICH_DATA CI_END="4.0042174346735635" CI_START="0.6937130221062111" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.6025176522525849" LOG_CI_START="-0.15882015301987223" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="6" O_E="0.0" SE="0.447213595499958" STUDY_ID="STD-Yapicioglu-2003" TOTAL_1="6" TOTAL_2="6" VAR="0.20000000000000004" WEIGHT="50.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.9846277727482295" CI_START="0.16709476979564683" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.7770371436699752" LOG_CI_START="-0.7770371436699752" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2008-06-10 10:41:50 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="12.61928762647337" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Fibrinolytic therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Fibrinolytic therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.55730570082838" CI_START="0.0796349172206608" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.09889646704573" LOG_CI_START="-1.09889646704573" LOG_EFFECT_SIZE="0.0" ORDER="7" O_E="0.0" SE="1.2909944487358056" STUDY_ID="STD-Luciano-1997" TOTAL_1="6" TOTAL_2="6" VAR="1.6666666666666665" WEIGHT="50.0"/>
<DICH_DATA CI_END="12.55730570082838" CI_START="0.0796349172206608" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.09889646704573" LOG_CI_START="-1.09889646704573" LOG_EFFECT_SIZE="0.0" ORDER="8" O_E="0.0" SE="1.2909944487358056" STUDY_ID="STD-Yapicioglu-2003" TOTAL_1="6" TOTAL_2="6" VAR="1.6666666666666665" WEIGHT="50.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="61.7381697935959" CI_START="0.1457769161296642" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.7905537508292086" LOG_CI_START="-0.8363112413898838" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2008-06-10 10:42:01 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.4764758426845582" Q="0.0" RANDOM="NO" SCALE="61.80097841387084" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.7119821370942422">
<NAME>Meningitis</NAME>
<GROUP_LABEL_1>Fibrinolytic therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Fibrinolytic therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="61.7381697935959" CI_START="0.1457769161296642" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7905537508292086" LOG_CI_START="-0.8363112413898838" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="9" O_E="0.0" SE="1.5430334996209192" STUDY_ID="STD-Luciano-1997" TOTAL_1="6" TOTAL_2="6" VAR="2.380952380952381" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="10" O_E="0.0" SE="0.0" STUDY_ID="STD-Yapicioglu-2003" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="61.7381697935959" CI_START="0.1457769161296642" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.7905537508292086" LOG_CI_START="-0.8363112413898838" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2008-06-10 10:42:09 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.4764758426845582" Q="0.0" RANDOM="NO" SCALE="62.81831458281831" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.7119821370942422">
<NAME>Secondary IVH</NAME>
<GROUP_LABEL_1>Fibrinolytic therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Fibrinolytic therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="61.7381697935959" CI_START="0.1457769161296642" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7905537508292086" LOG_CI_START="-0.8363112413898838" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="11" O_E="0.0" SE="1.5430334996209192" STUDY_ID="STD-Luciano-1997" TOTAL_1="6" TOTAL_2="6" VAR="2.380952380952381" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12" O_E="0.0" SE="0.0" STUDY_ID="STD-Yapicioglu-2003" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>